Remedy Pharmaceuticals Issues Second Quarter 2016 Report

PRESS RELEASE

Remedy Pharmaceuticals Issues Second Quarter 2016 Report

NEW YORK, New York, July 6, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced that the Company issued a second-quarter 2016 report.

Highlights include newly analyzed data from 12-month follow-ups of patients in its Phase 2 randomized, double blind trial of CIRARA™ in large hemispheric infarctions.

The report may be downloaded at http://www.remedypharmaceuticals.com/investor-information.html. 

ABOUT CIRARA

CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders.

Contact:

Remedy Pharmaceuticals
Sven Jacobson
212-586-2226 x 225
sven@remedypharmaceuticals.com